# Collegium Pharmaceutical, Inc: financial statements, quarterly

COLL · Nasdaq · CIK 1267565 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/coll.md) · [Financials](/companies/coll/financials.md) · [Filings](/companies/coll/filings.md) · [Insiders](/companies/coll/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/coll/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [137](/filings/0001558370-25-001801.md) | [150](/filings/0001558370-25-001801.md) | [145](/filings/0001628280-26-011992.md) | [145](/filings/0001628280-26-011992.md) | [159](/filings/0001628280-26-011992.md) | [182](/filings/0001628280-26-011992.md) | [178](/filings/0001628280-26-031697.md) | [188](/filings/0001628280-26-053851.md) | [209](/filings/0001628280-26-011992.md) | [205](/filings/0001628280-26-011992.md) | [194](/filings/0001628280-26-031697.md) | [200](/filings/0001628280-26-053851.md) |
| Cost of revenue | $m | [56.4](/filings/0001558370-25-001801.md) | [55.1](/filings/0001558370-25-001801.md) | [53.5](/filings/0001628280-26-011992.md) | [54.5](/filings/0001628280-26-011992.md) | [62.5](/filings/0001628280-26-011992.md) | [83.7](/filings/0001628280-26-011992.md) | [80.4](/filings/0001628280-26-031697.md) | [79.6](/filings/0001628280-26-053851.md) | [80.2](/filings/0001628280-26-011992.md) | [77.1](/filings/0001628280-26-011992.md) | [76.3](/filings/0001628280-26-031697.md) | [89.6](/filings/0001628280-26-053851.md) |
| Gross profit | $m | [80.3](/filings/0001558370-25-001801.md) | [94.6](/filings/0001558370-25-001801.md) | [91.5](/filings/0001628280-26-011992.md) | [90.8](/filings/0001628280-26-011992.md) | [96.8](/filings/0001628280-26-011992.md) | [98.3](/filings/0001628280-26-011992.md) | [97.3](/filings/0001628280-26-031697.md) | [108](/filings/0001628280-26-053851.md) | [129](/filings/0001628280-26-011992.md) | [128](/filings/0001628280-26-011992.md) | [117](/filings/0001628280-26-031697.md) | [110](/filings/0001628280-26-053851.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [35.3](/filings/0001558370-25-001801.md) | [32.9](/filings/0001558370-25-001801.md) | [42.0](/filings/0001628280-26-011992.md) | [43.3](/filings/0001628280-26-011992.md) | [62.0](/filings/0001628280-26-011992.md) | [63.1](/filings/0001628280-26-011992.md) | [76.4](/filings/0001628280-26-031697.md) | [73.6](/filings/0001628280-26-053851.md) | [67.1](/filings/0001628280-26-011992.md) | [67.6](/filings/0001628280-26-011992.md) | [86.4](/filings/0001628280-26-031697.md) | [107](/filings/0001628280-26-053851.md) |
| Operating income | $m | [45.0](/filings/0001558370-25-001801.md) | [61.7](/filings/0001558370-25-001801.md) | [49.5](/filings/0001628280-26-011992.md) | [47.5](/filings/0001628280-26-011992.md) | [34.8](/filings/0001628280-26-011992.md) | [38.1](/filings/0001628280-26-011992.md) | [21.7](/filings/0001628280-26-031697.md) | [35.1](/filings/0001628280-26-053851.md) | [62.1](/filings/0001628280-26-011992.md) | [60.8](/filings/0001628280-26-011992.md) | [30.9](/filings/0001628280-26-031697.md) | [3.7](/filings/0001628280-26-053851.md) |
| Interest expense | $m | [20.8](/filings/0001558370-24-001526.md) | [19.3](/filings/0001558370-24-001526.md) | [17.3](/filings/0001558370-24-007601.md) | [15.6](/filings/0001628280-26-011992.md) | [18.4](/filings/0001628280-26-011992.md) | [22.7](/filings/0001628280-26-011992.md) | [20.8](/filings/0001628280-26-031697.md) | [20.5](/filings/0001628280-26-053851.md) | [21.8](/filings/0001628280-26-011992.md) | [19.3](/filings/0001628280-26-011992.md) | [15.9](/filings/0001628280-26-031697.md) | [19.5](/filings/0001628280-26-053851.md) |
| Income tax | $m | [8.1](/filings/0001558370-25-001801.md) | [14.8](/filings/0001558370-25-001801.md) | [8.9](/filings/0001628280-26-011992.md) | [9.5](/filings/0001628280-26-011992.md) | [6.2](/filings/0001628280-26-011992.md) | [4.7](/filings/0001628280-26-011992.md) | [0.7](/filings/0001628280-26-031697.md) | [5.0](/filings/0001628280-26-053851.md) | [11.9](/filings/0001628280-26-011992.md) | [12.1](/filings/0001628280-26-011992.md) | [4.2](/filings/0001628280-26-031697.md) | [1.5](/filings/0001628280-26-053851.md) |
| Net income | $m | [20.6](/filings/0001558370-25-001801.md) | [31.9](/filings/0001558370-25-001801.md) | [27.7](/filings/0001628280-26-011992.md) | [19.6](/filings/0001628280-26-011992.md) | [9.3](/filings/0001628280-26-011992.md) | [12.5](/filings/0001628280-26-011992.md) | [2.4](/filings/0001628280-26-053851.md) | [12.0](/filings/0001628280-26-053851.md) | [31.5](/filings/0001628280-26-011992.md) | [17.0](/filings/0001628280-26-011992.md) | [14.5](/filings/0001628280-26-053851.md) | [(15.1)](/filings/0001628280-26-053851.md) |
| Diluted EPS | $ per share | [0.53](/filings/0001558370-25-001801.md) | [0.82](/filings/0001558370-25-001801.md) | [0.71](/filings/0001628280-26-011992.md) | [0.52](/filings/0001628280-26-011992.md) | [0.27](/filings/0001628280-26-011992.md) | [0.36](/filings/0001628280-26-011992.md) | [0.07](/filings/0001628280-26-031697.md) | [0.34](/filings/0001628280-26-053851.md) | [0.84](/filings/0001628280-26-011992.md) | [0.46](/filings/0001628280-26-011992.md) | [0.40](/filings/0001628280-26-031697.md) | [(0.46)](/filings/0001628280-26-053851.md) |
| Basic EPS | $ per share | [0.61](/filings/0001558370-25-001801.md) | [0.99](/filings/0001558370-25-001801.md) | [0.86](/filings/0001628280-26-011992.md) | [0.60](/filings/0001628280-26-011992.md) | [0.29](/filings/0001628280-26-011992.md) | [0.39](/filings/0001628280-26-011992.md) | [0.08](/filings/0001628280-26-031697.md) | [0.38](/filings/0001628280-26-053851.md) | [1.00](/filings/0001628280-26-011992.md) | [0.54](/filings/0001628280-26-011992.md) | [0.45](/filings/0001628280-26-031697.md) | [(0.46)](/filings/0001628280-26-053851.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [259](/filings/0001558370-24-014858.md) | [239](/filings/0001628280-26-011992.md) | [229](/filings/0001558370-25-006960.md) | [173](/filings/0001558370-25-010649.md) | [39.0](/filings/0001104659-25-107391.md) | [70.6](/filings/0001628280-26-011992.md) | [96.2](/filings/0001628280-26-031697.md) | [117](/filings/0001628280-26-053851.md) | [150](/filings/0001104659-25-107391.md) | [231](/filings/0001628280-26-053851.md) | [269](/filings/0001628280-26-031697.md) | [129](/filings/0001628280-26-053851.md) |
| Current assets | $m | [537](/filings/0001558370-23-017983.md) | [538](/filings/0001558370-25-001801.md) | [539](/filings/0001558370-24-007601.md) | [510](/filings/0001558370-24-011586.md) | [444](/filings/0001558370-24-014858.md) | [482](/filings/0001628280-26-011992.md) | [528](/filings/0001558370-25-006960.md) | [549](/filings/0001558370-25-010649.md) | [614](/filings/0001104659-25-107391.md) | [691](/filings/0001628280-26-053851.md) | [746](/filings/0001628280-26-031697.md) | [608](/filings/0001628280-26-053851.md) |
| Total assets | $m | [1,178](/filings/0001558370-23-017983.md) | [1,143](/filings/0001558370-25-001801.md) | [1,114](/filings/0001558370-24-007601.md) | [1,053](/filings/0001558370-24-011586.md) | [1,635](/filings/0001558370-24-014858.md) | [1,664](/filings/0001628280-26-011992.md) | [1,631](/filings/0001558370-25-006960.md) | [1,593](/filings/0001558370-25-010649.md) | [1,607](/filings/0001104659-25-107391.md) | [1,657](/filings/0001628280-26-053851.md) | [1,652](/filings/0001628280-26-031697.md) | [2,136](/filings/0001628280-26-053851.md) |
| Current liabilities | $m | [465](/filings/0001558370-23-017983.md) | [458](/filings/0001558370-25-001801.md) | [446](/filings/0001558370-24-007601.md) | [462](/filings/0001558370-24-011586.md) | [459](/filings/0001558370-24-014858.md) | [510](/filings/0001628280-26-011992.md) | [487](/filings/0001558370-25-006960.md) | [465](/filings/0001558370-25-010649.md) | [453](/filings/0001104659-25-107391.md) | [440](/filings/0001628280-26-053851.md) | [435](/filings/0001628280-26-031697.md) | [590](/filings/0001628280-26-053851.md) |
| Total liabilities | $m | [999](/filings/0001558370-23-017983.md) | [948](/filings/0001558370-25-001801.md) | [892](/filings/0001558370-24-007601.md) | [837](/filings/0001558370-24-011586.md) | [1,401](/filings/0001558370-24-014858.md) | [1,435](/filings/0001628280-26-011992.md) | [1,397](/filings/0001558370-25-006960.md) | [1,360](/filings/0001558370-25-010649.md) | [1,333](/filings/0001104659-25-107391.md) | [1,355](/filings/0001628280-26-053851.md) | [1,340](/filings/0001628280-26-031697.md) | [1,824](/filings/0001628280-26-053851.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [179](/filings/0001558370-24-014858.md) | [195](/filings/0001628280-26-011992.md) | [222](/filings/0001104659-25-107391.md) | [217](/filings/0001104659-25-107391.md) | [234](/filings/0001104659-25-107391.md) | [229](/filings/0001628280-26-053851.md) | [234](/filings/0001628280-26-053851.md) | [232](/filings/0001628280-26-053851.md) | [275](/filings/0001104659-25-107391.md) | [302](/filings/0001628280-26-053851.md) | [312](/filings/0001628280-26-053851.md) | [312](/filings/0001628280-26-053851.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [74.0 d](/filings/0001558370-24-014858.md) | [73.3 d](/filings/0001628280-26-011992.md) | [61.9](/filings/0001558370-25-006960.md) | [67.4 d](/filings/0001558370-25-010649.md) | [(9.0) d](/filings/0001104659-25-107391.md) | [84.6 d](/filings/0001628280-26-011992.md) | [55.4](/filings/0001628280-26-031697.md) | [72.4 d](/filings/0001628280-26-053851.md) | [78.4 d](/filings/0001104659-25-107391.md) | [123 d](/filings/0001628280-26-011992.md) | [57.1](/filings/0001628280-26-031697.md) | [71.3 d](/filings/0001628280-26-053851.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001558370-24-014858.md) | [0.2 d](/filings/0001628280-26-011992.md) | [0.6](/filings/0001558370-25-006960.md) | [0.3 d](/filings/0001558370-25-010649.md) | [0.2 d](/filings/0001104659-25-107391.md) | [0.6 d](/filings/0001628280-26-011992.md) | [0.8](/filings/0001628280-26-031697.md) | [0.1 d](/filings/0001628280-26-053851.md) | [0.2 d](/filings/0001104659-25-107391.md) | [0.7 d](/filings/0001628280-26-011992.md) | [0.3](/filings/0001628280-26-031697.md) | [0.5 d](/filings/0001628280-26-053851.md) |
| Share repurchases | $m | not reported | [25.0 d](/filings/0001628280-26-011992.md) | not reported | not reported | [0.0 d](/filings/0001104659-25-107391.md) | [25.0 d](/filings/0001628280-26-011992.md) | not reported | [25.1](/filings/0001628280-26-053851.md) | [0.0 d](/filings/0001104659-25-107391.md) | [0.0 d](/filings/0001628280-26-011992.md) | not reported | [0.0](/filings/0001628280-26-053851.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [42.1](/filings/0001558370-25-001801.md) | [41.3](/filings/0001558370-25-001801.md) | [41.4](/filings/0001628280-26-011992.md) | [40.4](/filings/0001628280-26-011992.md) | [40.2](/filings/0001628280-26-011992.md) | [40.1](/filings/0001628280-26-011992.md) | [32.8](/filings/0001628280-26-031697.md) | [39.1](/filings/0001628280-26-053851.md) | [39.4](/filings/0001628280-26-011992.md) | [40.1](/filings/0001628280-26-011992.md) | [40.1](/filings/0001628280-26-031697.md) | [32.5](/filings/0001628280-26-053851.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 32,555,613 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-053851.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.